Alambic Investment Management L.P. Sells 24,400 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Alambic Investment Management L.P. lowered its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 29.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 57,851 shares of the biotechnology company’s stock after selling 24,400 shares during the period. Alambic Investment Management L.P.’s holdings in Ironwood Pharmaceuticals were worth $867,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Ironwood Pharmaceuticals by 128.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 5,069 shares during the period. Gerber Kawasaki Wealth & Investment Management purchased a new position in Ironwood Pharmaceuticals during the 3rd quarter valued at about $170,000. Ameritas Investment Partners Inc. raised its holdings in Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after buying an additional 648 shares during the last quarter. Virtu KCG Holdings LLC raised its holdings in Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after buying an additional 1,470 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in Ironwood Pharmaceuticals by 30.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 23,405 shares of the biotechnology company’s stock worth $369,000 after buying an additional 5,527 shares during the last quarter.

In other news, insider Mark G. Currie sold 60,000 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $15.45, for a total value of $927,000.00. Following the transaction, the insider now owns 835,000 shares of the company’s stock, valued at $12,900,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the transaction, the chief executive officer now directly owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,905 shares of company stock valued at $2,666,359. Company insiders own 7.63% of the company’s stock.

Ironwood Pharmaceuticals, Inc. (IRWD) opened at $14.49 on Thursday. The firm has a market cap of $2,170.00, a P/E ratio of -15.09 and a beta of 1.28. Ironwood Pharmaceuticals, Inc. has a 12-month low of $12.89 and a 12-month high of $19.94. The company has a debt-to-equity ratio of -22.31, a current ratio of 4.87 and a quick ratio of 4.86.

Several research analysts have issued reports on IRWD shares. BidaskClub cut shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 30th. Morgan Stanley reaffirmed a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. Bank of America lowered shares of Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $20.00 to $15.00 in a research note on Friday, January 5th. Zacks Investment Research lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, ValuEngine lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 29th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $17.56.

TRADEMARK VIOLATION NOTICE: “Alambic Investment Management L.P. Sells 24,400 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/02/15/alambic-investment-management-l-p-has-867000-holdings-in-ironwood-pharmaceuticals-inc-irwd.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply